Abstract: The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune complexes of the present invention comprise a monoclonal antibody specific for binding to complement receptor (CR2) site on B lymphocytes linked to a target antigen. As shown in FIG. SA-SD immune complexes bound to monkey B cells are removed in concert with loss of CR2. FIGS. SA and SB demonstrate the % A1488 HB135 and % APhCy CD21 positive cells, out of the doubly positive FE CD20/PerCF CD45 population over time, after injection of A1488 labeled HB135 (an anti-CR2 antibody, administration indicated by first arrow) followed by injection of rabbit anti-mouse IgG (administration indicated by the second arrow). FIGS. SC and SD are plots of the molecules of equivalent soluble fluorochome (MESF) values for these populations.

Abstract: The present invention relates to the treatment, inhibition and prevention of cancer by the administration of anti-C3b(i) antibodies. The invention also relates to the treatment, inhibition and prevention of cancer by the administration of IgM antibodies and/or complement components prior to the administration of anti-C3b(i) antibodies. The present invention further relates to the detection, imaging, diagnosis and monitoring of cancer utilizing C3b(i) specific antibodies.

Abstract: The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune complexes of the present invention comprise a monoclonal antibody specific for binding to complement receptor (CR2) site on B lymphocytes linked to a target antigen. As shown in FIG. SA-SD immune complexes bound to monkey B cells are removed in concert with loss of CR2. FIGS. SA and SB demonstrate the % AI488 HB135 and % APhCy CD21 positive cells, out of the doubly positive FE CD20/PerCF CD45 population over time, after injection of A1488 labeled HB135 (an anti-CR2 antibody, administration indicated by first arrow) followed by injection of rabbit anti-mouse IgG (administration indicated by the second arrow). FIGS. SC and SD are plots of the molecules of equivalent soluble fluorochome (MESF) values for these populations.

Abstract: The present invention relates to the treatment and prevention of cancer, viral infections and microbial infections by the administration of anti-C3b(i) antibodies. The present invention also relates to methods of treating and preventing cancer, viral infection, or microbial infection in an animal comprising administering to said animal IgG antibodies, IgM antibodies and/or complement components in combination with antibodies specific for C3b(i). The present invention also relates methods of treating and preventing cancer, viral infection or microbial infection in an animal comprising administrating said animal antibodies that immunospecifically bind to one or more cancer cell antigens, viral antigens or microbial antigens, respectively, in combination with antibodies immunospecific for C3b(i). The present invention further relates to the detection, imaging, diagnosis and monitoring of cancer utilizing C3b(i) specific antibodies.

Abstract: Constructs consisting of antigen-based heteropolymers (AHP's) are provided. The antigen-based heteropolymers comprise at least one monoclonal antibody specific for binding to complement receptor (CR1) site on a human or non-human primate erythrocyte, and the anti-CR1 monoclonal antibody is crosslinked to an antigen specific for a target pathogenic autoantibody. Further provided is a method for treating autoimmune diseases in human or non-human primates using the AHP.

Abstract: Mammalian red blood cells are used to safely and rapidly neutralize and/or clear antigens or immunogens from the circulatory system by binding to the RBC a monoclonal antibody specific for a receptor (CR1) on the RBC, which monoclonal antibody is chemically bound to a second Mab specific for the antigen to be cleared from the circulatory system. These chemically cross-linked monoclonal antibody heteropolymers may be injected directly into the patient's circulatory system. Alternatively, red blood cells, extracted from the patient or provided by a suitable donor, are bound to the Mab complex and returned to the system.

Abstract: Mammalian red blood cells are used to safely and rapidly neutralize and/or clear antigens or immunogens from the circulatory system by binding to the RBC a monoclonal antibody specific for a receptor (CR1) on the RBC, which monoclonal antibody is chemically bound to a second Mab specific for the antigen to be cleared from the circulatory system. These chemically cross-linked monoclonal antibody heteropolymers may be injected directly into the patient's circulatory system. Alternatively, red blood cells, extracted from the patient or provided by a suitable donor, are bound to the Mab complex and returned to the system.

Abstract: A monoclonal antibody MHS-5 which specifically binds to a seminal vesicle specific antigen, SVSA, wherein the seminal vesicle specific antigen is secreted by the principal cells of the seminal vesicle epithelium. The method for producing this monoclonal antibody is also disclosed.

Abstract: A new probe for forensic analysis of sexual assaults is disclosed. The probe is a monoclonal antibody to a new protein marker, MHS-5, in semen. Also disclosed is the hybridoma producing the antibody as well as an assay utilizing the antibody for forensic analysis of criminal evidence.